Intravesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of bladder.

被引：0
|
作者：
Bouzid, K
Ferhat, R
Bounedjar, A
Mahfouf, H
Smaili, F
Adjali, K
机构：
[1] EHS Pierre & Marie Curie Ctr, Algiers, Algeria
[2] CAC Blida, Blida, Algeria
[3] CHU Bab Oued, Algiers, Algeria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4601
引用
收藏
页码：407S / 407S
页数：1
相关论文
共 50 条
  • [1] Intra vesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of the bladder: Final results
    Bounedjar, A.
    Ferhat, R.
    Smaili, F.
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial transitional cell carcinoma (TCC) of the bladder
    Smaili, F.
    Bounedjar, A.
    Ferhat, R.
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Intravesical gemcitabine in management of BCG refractory superficial transitional cell carcinoma (TCC) of urinary bladder
    Mohanty, N. K.
    Nayak, R. L.
    Arora, R. P.
    Saxena, S.
    [J]. BJU INTERNATIONAL, 2007, 99 : 14 - 14
  • [4] Evaluation of superficial bladder transitional cell carcinoma (TCC)
    不详
    [J]. JOURNAL OF ENDOUROLOGY, 2004, 18 : A38 - A38
  • [5] Predictors of outcome in bladder transitional cell carcinoma (TCC) treated by intravesical chemotherapy.
    White, RD
    Deitch, AD
    Daneshmand, S
    Blumenstein, BB
    [J]. JOURNAL OF UROLOGY, 1998, 159 (05): : 145 - 145
  • [6] The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder.
    Dash, A
    Koppie, T
    Vora, K
    Bochner, B
    Galsky, MD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 399S - 399S
  • [7] Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: A phase I and pharmacokinetic study
    Laufer, M
    Ramalingam, S
    Schoenberg, MP
    Haisfield-Wolf, ME
    Zuhowski, EG
    Trueheart, IN
    Eisenberger, MA
    Nativ, O
    Egorin, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 697 - 703
  • [8] Pharmacogenetics determinants of anticancer activity of intravescical gemcitabine in patients with superficial transitional cell carcinoma (TCC) of the bladder
    Verweij, Fabrizio
    Matel, Victor D.
    Scardino, Epifanio
    Rocco, Bernardo
    Musi, Gennaro
    Besana, Umberto
    Zambito, Stefano
    Pimentel, Marcelo
    Pedroso, Eduardo
    de Cobelli, Ottavio
    de Braud, Filippo
    Curigliano, Giuseppe
    Spitaleri, Gianluca
    Pece, Salvatore
    Danesi, Romano
    Mey, Valentina
    Giovanetti, Elisa
    Nanizzi, Sara
    [J]. JOURNAL OF UROLOGY, 2007, 177 (04): : 81 - 81
  • [9] Pharmacogenetics determinants of anticancer activity of intravescical gemcitabine in patients with superficial transitional cell carcinoma (TCC) of the bladder
    De Braud, Filippo
    Danesi, Romano
    Curigliano, Giuseppe
    Giovanetti, Elisa
    De Cobelli, Ottavio
    De Pas, Tommaso
    Mey, Valentina
    Spitaleri, Gianluca
    Pece, Salvatore
    Noberasco, Cristina
    Nannizzi, Sara
    Verweij, Fabrizio
    Renne, Giuseppe
    McVie, Gordon
    Del Tacca, Mario
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [10] Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder.
    Smith, DC
    Bhandari, M
    Hussain, M
    Montie, JE
    Wood, DP
    Lee, CT
    Petrylak, DP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 392S - 392S
12345